Replies to post #308467 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

falconer66a

Conventional drugs, such as those new ones targeting the protein wastes that cause Alzheimer's disease (tau tangles, beta-amyloid deposits), work downstream from the real problem, after it's caused disease. Just the opposite for Anavex 2-73 (blarcamesine). By propitiously activating the sigma-1 receptor protein, that protein can then continue to chaperone and modulate a diversity of "downstream" processes; restoring their normal function. With that, as in youth or before Alzheimer's set in, neurons can continue to gather and destroy the pathogenic waste proteins (a function of blarcamesine's induced/restored autophagy).

Blarcamesine has no disqualifying side effects because it doesn't inadvertently disrupt any essential biochemical process. Just the opposite. It restores those processes (autophagy, homeostasis, protein folding, chromatin modulation, many others). Not the case, at all, with most nerve-acting drugs./


Falconer. Very much appreciate your practical, sensible updates of A2-73. The more I read about our MOA the more convinced I am that this theme will continue in other human systems also. Recent pubs on uses and effects of TCE was an eye opener for me ,ref PD, etal. So, even though AVXL are on," a path less traveled by". It is certainly the correct path. As the "wizard of ID" says, "We found the enemy and it is us".

Keep up your solid contributions, TIA.